{rfName}

License and use

Altmetrics

Analysis of institutional authors

Bernal-Sprekelsen MAuthorMullol JAuthor
Share
Publications
>
Article

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Publicated to:Rhinology. 61 (3): 194-202 - 2023-01-01 61(3), DOI: 10.4193/rhin22.489

Authors: Fokkens, W J; Viskens, An-Sofie; Backer, Vibeke; Conti, Diego; de Corso, Eugenio; Gevaert, Philippe; Scadding, Glenis K; Wagemann, Martin; Sprekelsen, Manuel Bernal; Chaker, Adam; Heffler, Enrico; Han, Joseph K; Hopkins, Claire; Mullol, Joaquim; Peters, Anju; Reitsma, Sietze; Senior, Brent A; Hellings, Peter W

Affiliations

- Author
Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, Locat AMC, Room A2-230 - Author
Eastern Virginia Med Sch, Dept Otolaryngol & Head & Neck Surg - Author
European Forum Res & Educ Allergy & Airway Dis Sc - Author
Guys & St Thomas Hosp, Ear Nose & Throat Dept - Author
Hosp Clin Barcelona, Dept Otorhinolaryngol - Author
Humanitas Univ, Dept Biomed Sci, Pieve Emanuele - Author
Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol - Author
Royal Natl ENT Hosp, Dept Allergy & Rhinol - Author
Tech Univ Munich, TUM Sch Med, Klinikum Rechts Isar, Ctr Allergy & Environm ZAUM - Author
Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol - Author
Univ Antwerp, Fac Med & Hlth Sci - Author
Univ Barcelona, Hosp Clin, ENT Dept, Smell Clin,IDIBAPS,CIBERES - Author
Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCSS, Dept Otolaryngol Head & Neck Surg - Author
Univ Copenhagen, Dept ENT Head & Neck Surg & Audiol, Rigshosp - Author
Univ Hosp Ghent, Dept Otorhinolaryngol, Lab Upper Airways Res - Author
Univ Klinikum Dusseldorf, Dept Otorhinolaryngol - Author
Univ N Carolina, Dept Otolaryngol Head & Neck Surg - Author
UZ Leuven, Dept otorhinolaryngol Head & Neck Surg - Author
See more

Abstract

Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed. © 2023, International Rhinologic Society. All rights reserved.

Keywords
Biological productBiological productsBiologicsBiomarkersChronic diseaseChronic rhinosinusitisHumanHumansIndicationNasal polypsNose polypPatient selectionQuality of lifeRhinitisSinusitisThera-peutic responseType 2 inflammation

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Rhinology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 3/66, thus managing to position itself as a Q1 (Primer Cuartil), in the category Otorhinolaryngology. Notably, the journal is positioned above the 90th percentile.

This publication has been distinguished as a “Highly Cited Paper” by the agencies WoS (ESI, Clarivate) and ESI (Clarivate), meaning that it ranks within the top 1% of the most cited articles in its thematic field during the year of its publication. In terms of the observed impact of the contribution, this work is considered one of the most influential worldwide, as it is recognized as highly cited. (source consulted: ESI Nov 14, 2024)

And this is evidenced by the extremely high normalized impacts through some of the main indicators of this type, which, although dynamic over time and dependent on the set of average global citations at the time of calculation, already indicate that they are well above the average in different agencies:

  • Normalization of citations relative to the expected citation rate (ESI) by the Clarivate agency: 58.17 (source consulted: ESI Nov 14, 2024)
  • Weighted Average of Normalized Impact by the Scopus agency: 33.53 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 159.15 (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-10, the following number of citations:

  • WoS: 121
  • Scopus: 171
  • Europe PMC: 11
  • Open Alex: 103
  • OpenCitations: 57
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-10:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 142.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 142 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 11.
  • The number of mentions on the social network X (formerly Twitter): 2 (Altmetric).
Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Belgium; Denmark; Germany; Italy; Netherlands; United Kingdom; United States of America.